Developer docs
API playgroundTry for free, no card

Search company profiles

Cefaly Technology

Full company profile

uuid000679b

Namestring
Cefaly Technology
Legal namestring
CEFALY Technology SRL
Websiteurl
cefaly.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Cefaly Technology is a Belgium-headquartered medical device company that develops and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and preventive management of migraine. Founded in 2004 and headquartered in Liège with a U.S. subsidiary in Darien, Connecticut (established 2014), the company sells a portfolio of three device models — Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL — that deliver two treatment modes: a 60-minute Acute program for use at migraine onset and a 20-minute daily Prevent program for frequency reduction. The core technology uses a forehead-placed electrode secured via a proprietary magnetic attachment system that delivers precise electrical stimulation to the trigeminal nerve, with the Cefaly Connected variant adding Bluetooth connectivity that pairs with the CeCe companion mobile app for real-time treatment tracking, symptom logging, and integration with health platforms (Apple Health, Google Health, Garmin, Fitbit, Oura) through the Terra SDK.

The company monetizes primarily through one-time hardware sales of its devices via a direct-to-consumer e-commerce channel (cefaly.com and Shopify storefront), supplemented by recurring revenue from replacement electrodes sold through a subscription auto-delivery program. Both devices and electrodes are HSA/FSA eligible, and the company offers a 90-day money-back guarantee, financing through Affirm and PayPal Credit, and free one-on-one coaching to reduce purchase friction. Revenue is not publicly disclosed. The company holds a first-mover FDA regulatory position — first FDA-cleared device for migraine prevention (2014), first FDA clearance for acute treatment (2017), and OTC approval (2020) — and has accumulated outcomes data from over 300,000 users supported by ACME, TEAM, and PREMICE clinical studies.

Cefaly sells primarily to individual migraine sufferers via D2C, with the U.S. Veterans Health Administration serving as a major institutional channel — Cefaly Connected became the #1 prescribed neuromodulation device among VA providers in 2024, accounting for 53% of 21,593 prescriptions. The company also pursues clinician adoption through a provider certification program, distributes multi-language content (English, French, Spanish) across an active blog and social media presence, and serves customers in the U.S., Canada, and Europe. Leadership comprises CEO Andy Page, CTO John Bradbury, CFO Vincent Denis, and Medical Affairs Advisor Dr. Michael A. L. Johnson, with co-founders Pierre Rigaux and Pierre-Yves Muller historically associated with the company. Cefaly operates as a privately-held entity with no disclosed parent company, institutional investor, or recent funding round.

Short descriptiontext

Cefaly Technology develops FDA-cleared external trigeminal nerve stimulation (eTNS) devices for migraine treatment and prevention, selling direct-to-consumer and through the U.S. Veterans Health Administration, with a companion app and recurring electrode consumables.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDarien, United States
HQ citystring
Darien
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation devices, migraine treatment, nerve stimulation, medical devices, headache prevention
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

One-time sales of Cefaly neuromodulation devices (Cefaly Connected, Cefaly Enhanced) directly to consumers through e-commerce website. Devices are FDA-cleared for migraine treatment and prevention.

cefaly.com
2Electrode Consumables
TypeSubscription Recurring
Description

Recurring revenue from sale of replacement electrodes (sold in packs of 3). Electrodes are reusable and can be replenished through auto-delivery subscription with free shipping and 5% discount.

cefaly.com
3HSA/FSA Eligible Products
TypeHardware Sales
Description

Both devices and electrodes qualify as HSA/FSA eligible expenses, enabling customers to use pre-tax health account funds for purchases, expanding addressable market.

cefaly.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Cefaly Connected Device
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Specific price not publicly disclosed; includes device, zipper storage case, instruction manual, power adapter and cable. Covered through VA healthcare for U.S. veterans.

cefaly.com
2Electrode Subscription (Auto-delivery)
ModelSubscriptionBilling cadenceMonthly
Notes

Electrodes sold in packs of 3 (standard or hypoallergenic). Ships every 30/60/90 days with free shipping and 5% discount vs one-time purchase.

cefaly.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Cefaly Connected
Description

The primary connected neuromodulation device that pairs with the Cefaly app for real-time treatment tracking and monitoring.

cefaly.com
+3 more records
Core offering1 text field

Cefaly Technology designs, manufactures, and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and prevention of migraine. Its product line includes the Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL devices, supported by a Bluetooth-paired companion app (CeCe), reusable electrode consumables, and free one-on-one coaching services. The company sells primarily direct-to-consumer through its own e-commerce website and the Shopify storefront, with additional institutional distribution through the U.S. Veterans Health Administration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 79% of patients saw significant reduction in headache pain after 1 hour of Acute treatment
+3 more records
Product overview1 text field

CEFALY Technology offers a family of FDA-cleared external trigeminal nerve stimulation (eTNS) neuromodulation devices for migraine treatment and prevention. The product portfolio consists of three device models (CEFALY Connected, CEFALY Enhanced, and CEFALY DUAL) delivering two treatment modes: Acute (60-minute sessions for migraine relief) and Prevent (20-minute daily sessions for migraine prevention). CEFALY Connected integrates with the CEFALY Migraine Relief app (CeCe) via Bluetooth for real-time treatment monitoring, symptom tracking, and health data integration from wearables. The ecosystem is supported by consumable electrodes (standard and hypoallergenic), a free one-on-one coaching service, and a subscription program for electrode auto-delivery.

Product and service6 records
1Cefaly Connected
CategoryCore Product (Medical Device)
Description

Primary FDA-cleared eTNS neuromodulation device that stimulates the trigeminal nerve via a forehead electrode to treat and prevent migraines; features Bluetooth connectivity for app integration and real-time treatment monitoring. Sold direct-to-consumer with a 90-day money-back guarantee.

2Cefaly Enhanced
CategoryCore Product (Medical Device)
Description

FDA-cleared neuromodulation device for migraine treatment and prevention using external trigeminal nerve stimulation, featuring purple (Prevent) and aqua (Acute) LED indicators to differentiate treatment modes.

3Cefaly DUAL
CategoryCore Product (Medical Device)
Description

Earlier generation neuromodulation device with dual treatment modes (Prevent and Acute) for migraine relief, featuring green LED indicator lights.

4Cefaly Migraine Relief App (CeCe)
CategoryCompanion Software / Mobile App
Description

Free companion mobile application for Cefaly Connected that enables Bluetooth pairing, real-time treatment selection, adjustment and monitoring, migraine tracking, health data integration from wearables, and personalized migraine reports.

5Cefaly Electrodes
CategoryConsumable Accessory
Description

Adhesive electrode accessories for use with Cefaly devices, available in standard and hypoallergenic variants (for users with acrylate allergy); sold in packs of 3 with optional auto-delivery subscription.

6Cefaly Coach
CategoryCustomer Support Service
Description

Free one-on-one coaching service providing Cefaly users with assistance on device usage, treatment mode selection, intensity adjustment, troubleshooting, and app usage optimization.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine and cluster headache. It is the closest direct competitor to Cefaly — both are prescription/OTC neuromodulation devices targeting the same headache patient population with similar clinical and DTC strategies.

TypeDirect peer
Description

Theranica's Nerivio is a wearable remote electrical neuromodulation (REN) device for acute and preventive migraine treatment, controlled via smartphone app. It directly competes with Cefaly Connected in the connected, app-paired neuromodulation category for migraine.

TypeDirect peer
Description

eNeura manufactures the sTMS mini, a single-pulse transcranial magnetic stimulation device FDA-cleared for acute and preventive treatment of migraine. It competes with Cefaly in the neuromodulation-for-migraine category with a different stimulation modality (magnetic vs. electrical).

TypeBroad incumbent
Description

Saluda Medical develops implantable spinal cord and dorsal root ganglion stimulation systems for chronic pain and other neurological conditions. While implantable rather than external, it is a comparable neurostimulation medtech player addressing chronic neurological conditions with similar regulatory and clinical evidence requirements.

TypeBroad incumbent
Description

Axonics manufactures implantable sacral and pudendal neuromodulation devices for bladder/bowel dysfunction. As a public neuromodulation pure-play, it provides a comparable public-market benchmark for neurostimulation device economics and adoption curves.

TypeBroad incumbent
Description

Inspire Medical Systems produces an implantable hypoglossal nerve stimulation device for obstructive sleep apnea. It is a successful public neurostimulation medtech company and serves as a benchmark for the commercial trajectory of a single-indication neurostim device.

TypeBroad incumbent
Description

NeuroPace makes the RNS System, an implanted responsive neurostimulator for refractory epilepsy. It is an adjacent neurostimulation medtech company addressing chronic neurological conditions with similar regulatory, evidence, and clinician-adoption challenges as Cefaly.

TypeEmerging player
Description

Cala Health develops wearable transcutaneous afferent patterned stimulation (TAPS) therapy for essential tremor and other neurological conditions. It is an emerging wearable neurostim company targeting chronic neurological conditions with a similar consumer/clinical hybrid go-to-market model.

TypeOthers
Description

Major pharmaceutical manufacturers of migraine therapies (Botox, CGRP inhibitors like Aimovig, Emgality, and Reyvow) compete for the same neurologist prescriptions and patient population. They represent the principal non-device therapeutic alternatives Cefaly must differentiate against.

TypeEmerging player
Description

Helius Medical Technologies develops portable neuromodulation devices (PoNS) for neurological symptoms from traumatic brain injury and multiple sclerosis. It is an emerging non-invasive neurostim company addressing chronic neurological conditions via a prescription device model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cefaly Technology

Neuromodulation Medical Devicescefaly.com

Cefaly Technology develops FDA-cleared external trigeminal nerve stimulation (eTNS) devices for migraine treatment and prevention, selling direct-to-consumer and through the U.S. Veterans Health Administration, with a companion app and recurring electrode consumables.

What Cefaly Technology does

Cefaly Technology is a Belgium-headquartered medical device company that develops and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and preventive management of migraine. Founded in 2004 and headquartered in Liège with a U.S. subsidiary in Darien, Connecticut (established 2014), the company sells a portfolio of three device models — Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL — that deliver two treatment modes: a 60-minute Acute program for use at migraine onset and a 20-minute daily Prevent program for frequency reduction. The core technology uses a forehead-placed electrode secured via a proprietary magnetic attachment system that delivers precise electrical stimulation to the trigeminal nerve, with the Cefaly Connected variant adding Bluetooth connectivity that pairs with the CeCe companion mobile app for real-time treatment tracking, symptom logging, and integration with health platforms (Apple Health, Google Health, Garmin, Fitbit, Oura) through the Terra SDK.

The company monetizes primarily through one-time hardware sales of its devices via a direct-to-consumer e-commerce channel (cefaly.com and Shopify storefront), supplemented by recurring revenue from replacement electrodes sold through a subscription auto-delivery program. Both devices and electrodes are HSA/FSA eligible, and the company offers a 90-day money-back guarantee, financing through Affirm and PayPal Credit, and free one-on-one coaching to reduce purchase friction. Revenue is not publicly disclosed. The company holds a first-mover FDA regulatory position — first FDA-cleared device for migraine prevention (2014), first FDA clearance for acute treatment (2017), and OTC approval (2020) — and has accumulated outcomes data from over 300,000 users supported by ACME, TEAM, and PREMICE clinical studies.

Cefaly sells primarily to individual migraine sufferers via D2C, with the U.S. Veterans Health Administration serving as a major institutional channel — Cefaly Connected became the #1 prescribed neuromodulation device among VA providers in 2024, accounting for 53% of 21,593 prescriptions. The company also pursues clinician adoption through a provider certification program, distributes multi-language content (English, French, Spanish) across an active blog and social media presence, and serves customers in the U.S., Canada, and Europe. Leadership comprises CEO Andy Page, CTO John Bradbury, CFO Vincent Denis, and Medical Affairs Advisor Dr. Michael A. L. Johnson, with co-founders Pierre Rigaux and Pierre-Yves Muller historically associated with the company. Cefaly operates as a privately-held entity with no disclosed parent company, institutional investor, or recent funding round.

Cefaly Technology firmographics

Firmographics
Name
Cefaly Technology
Legal name
CEFALY Technology SRL
Website
https://cefaly.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Cefaly Technology develops FDA-cleared external trigeminal nerve stimulation (eTNS) devices for migraine treatment and prevention, selling direct-to-consumer and through the U.S. Veterans Health Administration, with a companion app and recurring electrode consumables.
Ownership category
akta.pro rank

Cefaly Technology industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Neuromodulation devices
  • Migraine treatment
  • Nerve stimulation
  • Medical devices
  • Headache prevention

Where Cefaly Technology is headquartered

Location

Headquarters

HQ city
Darien
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cefaly Technology business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: One-time sales of Cefaly neuromodulation devices (Cefaly Connected, Cefaly Enhanced) directly to consumers through e-commerce website. Devices are FDA-cleared for migraine treatment and prevention.
  2. Electrode Consumables: Recurring revenue from sale of replacement electrodes (sold in packs of 3). Electrodes are reusable and can be replenished through auto-delivery subscription with free shipping and 5% discount.
  3. HSA/FSA Eligible Products: Both devices and electrodes qualify as HSA/FSA eligible expenses, enabling customers to use pre-tax health account funds for purchases, expanding addressable market.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCefaly Connected Device
SubscriptionMonthlyElectrode Subscription (Auto-delivery)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Cefaly Technology product offering

Product offering

Core offering

Cefaly Technology designs, manufactures, and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and prevention of migraine. Its product line includes the Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL devices, supported by a Bluetooth-paired companion app (CeCe), reusable electrode consumables, and free one-on-one coaching services. The company sells primarily direct-to-consumer through its own e-commerce website and the Shopify storefront, with additional institutional distribution through the U.S. Veterans Health Administration.

Product overview

CEFALY Technology offers a family of FDA-cleared external trigeminal nerve stimulation (eTNS) neuromodulation devices for migraine treatment and prevention. The product portfolio consists of three device models (CEFALY Connected, CEFALY Enhanced, and CEFALY DUAL) delivering two treatment modes: Acute (60-minute sessions for migraine relief) and Prevent (20-minute daily sessions for migraine prevention). CEFALY Connected integrates with the CEFALY Migraine Relief app (CeCe) via Bluetooth for real-time treatment monitoring, symptom tracking, and health data integration from wearables. The ecosystem is supported by consumable electrodes (standard and hypoallergenic), a free one-on-one coaching service, and a subscription program for electrode auto-delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • Cefaly Connected: The primary connected neuromodulation device that pairs with the Cefaly app for real-time treatment tracking and monitoring.
  • Cefaly Enhanced
  • Cefaly DUAL
  • CeCe App

Products and services

  • Cefaly Connected Primary FDA-cleared eTNS neuromodulation device that stimulates the trigeminal nerve via a forehead electrode to treat and prevent migraines; features Bluetooth connectivity for app integration and real-time treatment monitoring. Sold direct-to-consumer with a 90-day money-back guarantee.
  • Cefaly Enhanced FDA-cleared neuromodulation device for migraine treatment and prevention using external trigeminal nerve stimulation, featuring purple (Prevent) and aqua (Acute) LED indicators to differentiate treatment modes.
  • Cefaly DUAL Earlier generation neuromodulation device with dual treatment modes (Prevent and Acute) for migraine relief, featuring green LED indicator lights.
  • Cefaly Migraine Relief App (CeCe) Free companion mobile application for Cefaly Connected that enables Bluetooth pairing, real-time treatment selection, adjustment and monitoring, migraine tracking, health data integration from wearables, and personalized migraine reports.
  • Cefaly Electrodes Adhesive electrode accessories for use with Cefaly devices, available in standard and hypoallergenic variants (for users with acrylate allergy); sold in packs of 3 with optional auto-delivery subscription.
  • Cefaly Coach Free one-on-one coaching service providing Cefaly users with assistance on device usage, treatment mode selection, intensity adjustment, troubleshooting, and app usage optimization.

Quantifiable outcome

  • 79% of patients saw significant reduction in headache pain after 1 hour of Acute treatment
  • +3 more outcomes

Companies that use Cefaly Technology

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Cefaly Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

Feature6 records

Cefaly Technology partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Cefaly Technology competitors and assessment

Company assessment

Direct peers

  • electroCore (gammaCore): electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine and cluster headache. It is the closest direct competitor to Cefaly — both are prescription/OTC neuromodulation devices targeting the same headache patient population with similar clinical and DTC strategies.
  • Theranica (Nerivio): Theranica's Nerivio is a wearable remote electrical neuromodulation (REN) device for acute and preventive migraine treatment, controlled via smartphone app. It directly competes with Cefaly Connected in the connected, app-paired neuromodulation category for migraine.
  • eNeura (sTMS mini): eNeura manufactures the sTMS mini, a single-pulse transcranial magnetic stimulation device FDA-cleared for acute and preventive treatment of migraine. It competes with Cefaly in the neuromodulation-for-migraine category with a different stimulation modality (magnetic vs. electrical).

Broad incumbents

  • Saluda Medical: Saluda Medical develops implantable spinal cord and dorsal root ganglion stimulation systems for chronic pain and other neurological conditions. While implantable rather than external, it is a comparable neurostimulation medtech player addressing chronic neurological conditions with similar regulatory and clinical evidence requirements.
  • Axonics Modulation Technologies: Axonics manufactures implantable sacral and pudendal neuromodulation devices for bladder/bowel dysfunction. As a public neuromodulation pure-play, it provides a comparable public-market benchmark for neurostimulation device economics and adoption curves.
  • Inspire Medical Systems: Inspire Medical Systems produces an implantable hypoglossal nerve stimulation device for obstructive sleep apnea. It is a successful public neurostimulation medtech company and serves as a benchmark for the commercial trajectory of a single-indication neurostim device.
  • NeuroPace: NeuroPace makes the RNS System, an implanted responsive neurostimulator for refractory epilepsy. It is an adjacent neurostimulation medtech company addressing chronic neurological conditions with similar regulatory, evidence, and clinician-adoption challenges as Cefaly.

Emerging players

  • Cala Health: Cala Health develops wearable transcutaneous afferent patterned stimulation (TAPS) therapy for essential tremor and other neurological conditions. It is an emerging wearable neurostim company targeting chronic neurological conditions with a similar consumer/clinical hybrid go-to-market model.
  • Helius Medical Technologies: Helius Medical Technologies develops portable neuromodulation devices (PoNS) for neurological symptoms from traumatic brain injury and multiple sclerosis. It is an emerging non-invasive neurostim company addressing chronic neurological conditions via a prescription device model.

Others

  • AbbVie (Botox) / Pfizer / Lilly (CGRP inhibitors): Major pharmaceutical manufacturers of migraine therapies (Botox, CGRP inhibitors like Aimovig, Emgality, and Reyvow) compete for the same neurologist prescriptions and patient population. They represent the principal non-device therapeutic alternatives Cefaly must differentiate against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cefaly Technology social profiles

Digital presence

Cefaly Technology compliance and trust

Trust signal

Compliance3 records

Cefaly Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cefaly Technology leadership team

Management profile

Number of profiles

Profiles7 records

Cefaly Technology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cefaly Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cefaly Technology

What does Cefaly Technology do?

Cefaly Technology designs, manufactures, and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and prevention of migraine. Its product line includes the Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL devices, supported by a Bluetooth-paired companion app (CeCe), reusable electrode consumables, and free one-on-one coaching services. The company sells primarily direct-to-consumer through its own e-commerce website and the Shopify storefront, with additional institutional distribution through the U.S. Veterans Health Administration.

Is Cefaly Technology a public or private company?

Cefaly Technology is a private company. It is classified as private equity controlled and is currently operating.

When was Cefaly Technology founded?

Cefaly Technology was founded in 2004. It employs 11 to 50 people.

Where is Cefaly Technology based?

Cefaly Technology is headquartered in Darien, United States, in the North America region.

How does Cefaly Technology make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are electrode Consumables and HSA/FSA Eligible Products.

Who are Cefaly Technology's main competitors?

Direct peers on record are electroCore (gammaCore), Theranica (Nerivio) and eNeura (sTMS mini). Broad incumbents are Saluda Medical, Axonics Modulation Technologies, Inspire Medical Systems and NeuroPace. Emerging players are Cala Health and Helius Medical Technologies. AbbVie (Botox) / Pfizer / Lilly (CGRP inhibitors) is listed as an others.

Does Cefaly Technology have an API?

No public API is recorded for Cefaly Technology.

What industry is Cefaly Technology in?

Cefaly Technology's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comDigital Migraine Treatment Device Market Expands with Non-Invasive Neuromodulation Technology | Cefaly Technology, Cirrus Healthcare Products, ElectroCore, Inc., eNeura Inc.The global digital migraine treatment device market was valued at USD 255 million in 2024 and is projected to reach USD 1.31 billion by 2033, a CAGR of 18.2%. Growth is driven by rising migraine prevalence, demand for non-invasive neuromodulation, and telehealth integration. The FDA cleared a wearable neuromodulation headset in the U.S. in 2025, and Japan piloted a smartphone-connected device in Tokyo clinics.PR NewswireCEFALY Technology Launches Headaches.com Resource for Neuromodulation Migraine TreatmentMedical device maker CEFALY Technology launched Headaches.com on June 4, 2024, as an educational resource for healthcare providers and migraine patients to learn about non-invasive neuromodulation treatment for migraine. The website provides medically reviewed information on external trigeminal nerve stimulation (eTNS) therapy, clinical study links, and conversation guides for discussing neuromodulation with patients. CEFALY is the only FDA-cleared over-the-counter device for migraine treatment and prevention available without a prescription, and the Belgium-based company has been providing this option for 15 years.PR NewswireCEFALY Technology Launches the CEFALY Cares Program by Providing Migraine Relief to Domestic Violence SurvivorsCEFALY Technology launched the CEFALY Cares program to provide its migraine treatment devices at no cost to nonprofit organizations serving domestic violence survivors in the United States. The initiative aims to address the link between trauma-induced stress and migraines by offering both hardware and educational resources to help women rebuild their lives.PR NewswireCEFALY Technology Selected to Present TEAM Study Findings at the Military Health System Research SymposiumCEFALY Technology will present findings from the TEAM study at the Military Health System Research Symposium in Kissimmee, Florida, August 14-17, 2023, highlighting results from the largest prospective multicenter randomized controlled trial on external trigeminal nerve stimulation for acute migraine treatment. The study found that 2-hour e-TNS therapy provided significantly higher rates of migraine resolution at 2 and 24 hours post-treatment with no serious adverse events reported, demonstrating a safe and effective non-pharmacological option for migraine sufferers. The company also announced a partnership with VA Health Care to provide drug-free migraine treatment to veterans, with U.S. service members experiencing migraine at three times the rate of civilians.PR NewswireCeCe Migraine Management App Syncs With CEFALY Connected Device to Provide Personalized Migraine InsightsCEFALY Technology has released an update to its CeCe Migraine Management app enabling synchronization with the Bluetooth-enabled CEFALY Connected wearable device, allowing users to track treatments, monitor sessions in real time, and log migraine attacks on their mobile device. The integration enables users to view session time remaining, battery life, and download PDF reports of their unique migraine patterns and treatment data to share with healthcare providers. CEFALY Technology, a Belgium-based company with U.S. offices in Darien, Connecticut, developed both the app and the FDA-cleared over-the-counter device, which uses external trigeminal nerve stimulation to treat and prevent migraines.PR NewswireCEFALY Technology Launches Trade-In Program for Purchasers of the New CEFALY Connected Migraine Treatment DeviceCEFALY Technology announced a trade-in program allowing owners of older CEFALY migraine treatment devices to receive credit toward purchasing the new CEFALY Connected, the company's first Bluetooth-enabled device that syncs with its mobile app. The trade-in credit amount varies based on the device type, with eligibility confirmed through customer service before ordering. The CEFALY Connected features a 7-hour battery life, softer migraine-friendly indicator lights, and allows users to track treatment sessions and log migraine attacks through the CeCe Migraine Management app.PR NewswireCEFALY Technology Introduces Bluetooth-Enabled CEFALY Connected Migraine Treatment DeviceMedical device maker CEFALY Technology unveiled the CEFALY Connected, a Bluetooth-enabled version of its FDA-cleared migraine treatment device, on December 15, 2022. The new device syncs with the CeCe Migraine Management app, allowing users to track treatments in real time, log migraine attacks, monitor battery life, and generate PDF reports to share with healthcare providers. The CEFALY Connected also features an improved 7-hour battery life and softer indicator lights, aiming to help users better understand their migraine patterns and optimize treatment plans.PR NewswireCEFALY Announces Complimentary Coaching Service to Help Users Achieve Success with Their Migraine TreatmentCEFALY Technology has launched a free, personalized one-on-one coaching service to help users maximize the effectiveness of their FDA-cleared External Trigeminal Nerve Stimulation migraine device. The CEFALY Coach program provides users with guidance on proper device usage, finding ideal stimulation intensity, and committing to a daily treatment regimen. The CEO stated that the coaching program empowers users to take control of their migraine treatment and achieve the best possible results with the device.NewswiseMigraine Treatment Device Maker CEFALY Technology Streamlines Subscription Experience With OrdergrooveCEFALY Technology has partnered with Ordergroove to launch an upgraded subscription service for its migraine treatment device electrodes. The new platform allows customers to automatically replenish supplies with benefits including a 5% discount and free shipping, aiming to improve adherence to preventive treatment plans.PR NewswireMigraine Treatment Device Maker CEFALY Technology Streamlines Subscription Experience With OrdergrooveCEFALY Technology has partnered with Ordergroove to launch an upgraded electrode subscription service for its FDA-cleared migraine treatment device, allowing customers to automatically replenish conductive gel electrodes with a 5% discount and free shipping. The announcement was made during Migraine and Headache Awareness Month, with CEFALY celebrating its eighth anniversary in the U.S. market and having treated two billion migraines to date.